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ABSTRACT Wedesigned,constructed,andevaluatedaprototypenovelreportersystemcomprisedoftwofunctionalcassettes:(i)
theSP6RNApolymerasegeneundertranscriptionalcontrolofapromoteractiveinmycobacteriaand(ii)theconsensusSP6
polymerasepromoterthatdirectsexpressionofanotherwiseunexpressedsequence.Weincorporatedthereportersystemintoa
mycobacteriophage for delivery into viable Mycobacterium tuberculosis, and introduction led to synthesis of an SP6 polymerase-
dependentsurrogatemarkerRNAthatwedetectedbyreversetranscriptasePCR(RT-PCR).Thereporterconﬁrmedthesuscepti-
bility proﬁle of both drug-susceptible and drug-resistant M. tuberculosis strains exposed to ﬁrst-line antitubercular drugs and
requiredaslittleas16hofexposuretoantibacterialagentstargetingbacterialmetabolicprocessestoaccuratelyreadthereac-
tion.Thereportersystemtranslatedthebacterialphenotypeintoalanguageinterpretablebyrapidandsensitivenucleicacid
detection. As a phenotypic assay that works only on viable M. tuberculosis, it could be used to rapidly assess resistance to any
drug,includingdrugsforwhichthemechanismofresistanceisunknownorwhichresultfrommanypotentialknown(andun-
known)geneticalterations.
IMPORTANCE The ability to detect antibiotic resistance of slow-growing bacteria (i.e., Mycobacterium tuberculosis) is hampered
bytwofactors,thetimetodetection(weekstomonths)andtheresistancemechanism(unknownformanydrugs),delayingthe
appropriatetreatmentofpatientswithdrug-resistantormultidrug-resistanttuberculosis(TB).Thenoveltechniquedescribedin
this article uses a unique surrogate nucleic acid marker produced by phage that infects M. tuberculosis to record phenotypic an-
tibioticsusceptibilityinlessthanaday.
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M
any reporter systems, such as lac promoter-controlled
-galactosidase for blue/white selection of recombinant
plasmids(1)orinvivoexpressionofﬂuorescentproteins(2,3),are
used as surrogate markers for biological phenomena that are not
easytomeasure.Thesereportersystemsproduceproductsthatare
easily and reliably detected. Reporter systems can also be intro-
duced into bacteriophages, obligate intracellular viruses that in-
fectbacteriaandusetheirbiosyntheticmachinerytomanufacture
andreleasephageprogeny.Theserecombinantphagescanbeused
toaccuratelyreportmetabolicactivityofinfectedcells:alivingcell
canbeco-optedforprogenyproduction,whileadeadcellcannot.
Detection of speciﬁc phage products or phage progeny, therefore,
indicatesbacterialmetabolicactivity.Becauseantimicrobialdrugs
ultimatelyaffectthemetaboliccapacityofasusceptiblepathogen,
antibiotics also have an effect on synthesis of both phage compo-
nents (i.e., reporter enzymes) and phage progeny.
Due to a notoriously slow doubling time of Mycobacterium
tuberculosis, standard antibiotic susceptibility tests using culture
take several weeks to months to complete. To solve this problem,
investigators generated a recombinant mycobacteriophage that
expressesﬁreﬂyluciferase.Afteradditionofaluciferinsubstrateto
phage-infectedcells,lightisproducedifthecellissufﬁcientlymet-
abolically active to support the phage infection and gene expres-
sion.Ifantibioticsaddedpriortophageinfectionareeffectiveand
disturbcellviabilityormetabolism,thedrugsusceptibilitypheno-
type is detected as a reduction in the level of light produced com-
pared to that for an untreated control. The assay works well in a
research laboratory setting, with spiked and late-stage tuberculo-
sis (TB) patient sputum, but the sputum processing procedure in
clinical laboratories is harsh toward M. tuberculosis, killing a large
percentageofthebacteriaandreducingsurfaceproteinsnecessary
forphageattachmentinthosethatsurvive.Thus,theoptimaltime
for reading this assay was nearly a week (2, 4). Moreover, we and
others found that the luciferase reporter phage assay required
104 bacteria to provide sufﬁcient light for automated detection,
and so it could not detect the low number of M. tuberculosis bac-
teria present in most patient samples (5). A recent adaptation of
theluciferasereporterphageassayreplacesluciferasewithﬂuores-
cent proteins that can be detected by ﬂuorescence microscopes
used for TB sputum smear microscopy or by ﬂuorescence-
activatedcellsorters(6).Sensitivityofthisassay,whenperformed
directly with clinical samples, is not yet established.
Other efforts to speed antibiotic susceptibility testing of M.
tuberculosis have been explored. For example, a phage ampliﬁca-
tion assay using wild-type mycobacteriophage D29 detects M. tu-
berculosis in TB patient samples and assesses antibiotic suscepti-
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two different mycobacteria: (i) M. tuberculosis in the patient’s
sample, which is infected with the phage and, if viable, produces
progeny, and (b) a fast-growing mycobacterium, grown to a bac-
teriallawn,onwhichtheM.tuberculosisphageprogenyareplated
to produce phage plaques. The plaques estimate the number of
phage progeny as a surrogate for the number of viable M. tuber-
culosis bacteria in the sample. This assay employs plaque forma-
tion on fast-growing Mycobacterium as the detection methodol-
ogy, rather than sophisticated luminometers, but the complexity
of the assay has limited its commercial application.
Although M. tuberculosis-speciﬁc nucleic acid tests can detect
the small numbers of M. tuberculosis present in a patient sample,
detection of drug resistance is restricted to just a few drugs; for
most drugs, the various genes and genetic mutations responsible
forclinicaldrugresistanceareeitherunknownortoonumerousto
test in a simple assay. Moreover, there is now evidence that some
forms of antibiotic evasion are epigenetic (10–12).
To address both sensitivity and timeliness of M. tuberculosis
antibiotic susceptibility testing, we combined into a single assay
theelementsofbothphenotypicandgenotypicmethods:arecom-
binant phage that reports the phenotypic effects antimicrobials
exert on susceptible bacteria, as well as a nucleic acid marker pro-
duced by the phage to speed assay time and improve sensitivity.
This prototype reporter phage encodes the SP6 RNA polymerase
gene expressed by a promoter active in mycobacteria. Once syn-
thesized and folded, SP6 polymerase transcribes a region under
exclusive transcriptional control of the SP6 consensus promoter.
The generation of this SP6 polymerase-dependent RNA is then
detected using nucleic acid detection systems. The SP6
polymerase-dependent RNA is an artiﬁcial nucleic acid marker
that has a unique sequence not present in nature and is termed a
surrogate marker locus (SML); the reporter system incorporated
into the phage that directs SML synthesis is the SML generation
module (SGM). In this article, we describe the design, construc-
tion, and utility of a prototype SGM to identify viable M. tubercu-
losis and report resistance to ﬁrst-line TB drugs. We document
SGMinsertionintoamycobacteriophagetocreatephSP6-ProPol,
a prototype SGM phage, and demonstrate SML synthesis during
SGM phage infection of mycobacteria to determine susceptibility
toﬁrst-lineanti-TBantibiotics.Thisisareportofproofofconcept
in a development program to create a new and novel type of re-
porter phage that allows rapid and ultrasensitive nucleic acid am-
pliﬁcation technologies to quantify cell viability.
RESULTS
The prototype encoded the SP6 RNA polymerase gene expressed
by a promoter active in mycobacteria. Once synthesized and
folded,SP6polymerasetranscribedaregionunderexclusivetran-
scriptional control of the SP6 consensus promoter. The genera-
tion of this SP6 polymerase-dependent RNA was then detected
using nucleic acid detection systems.
Construction of phSP6-ProPol, a prototype SGM phage. To
create phSP6-ProPol, the prototype SGM phage, we inserted the
SGM depicted in Fig. 1A into a targeting plasmid derived from
phAE142 as described in Materials and Methods. This insertion
resultedinreplacementofthePleftluciferasereportercassettewith
theSGM.ThetargetingplasmidwasthenusedtoreplacetheNotI
restriction fragment of phAE142 to create phSP6-ProPol
(Fig.1B).Infectiousphageweresubsequentlycreatedbytransfor-
mation of phSP6-ProPol phasmid DNA puriﬁed from indepen-
dent clones into the Mycobacterium smegmatis strain mc2 4502.
We conﬁrmed that SGM was present in the correct orientation in
infectiousphSP6-ProPolphagebythepresenceofaproductofthe
expected size when phage eluted from plaques were ampliﬁed by
PCR using a primer that hybridized to a site in TM4 outside the
transgenic sequences (TM4-50133.52) in combination with the
primerPLLF,whichhybridizedtothePleftpromoterpresentinthe
SGM. As a control, we ampliﬁed phSP6-ProPol phasmid DNA,
with or without MP buffer, and observed a product of the correct
size (Fig. 1C). The presence of MP buffer in the phasmid control
ampliﬁcation reaction resulted in reduced reaction efﬁciency and
suggested that MP buffer may have reduced the amount of prod-
uct obtained from ampliﬁcation of infectious phage, since it was
also used to elute phage from plugs of Noble agar. MP buffer
present in the ampliﬁcation reaction also slowed the migration of
products during agarose gel electrophoresis compared to results
with the phasmid DNA control. However, the PCR product was
clearly distinct in size from that produced by ampliﬁcation of
infectiousphAE142phage(Fig.1C).Figure1Ddemonstratesthat
nomajordeletionsoftheSP6RNApolymerasegenewerepresent,
because a single product consistent with the size of the full-length
SP6RNApolymeraseopenreadingframewasobtainedafterPCR
ampliﬁcation of infectious phage with primers PLLU and PLLD.
DetectionofSMLRNAinstocksofinfectiousphSP6-ProPol.
TodeﬁneconditionsthatreduceSMLRNAtoundetectablelevels
in the phage preparation itself, we added either 5 ng or 1 ng of
RNase A to 108 PFU of phSP6-ProPol and incubated the mixture
at37°Cfor30min.IntactRNAwasthenpuriﬁedandtreatedwith
DNaseI,andtheSMLwasampliﬁedbyreversetranscriptasePCR
(RT-PCR).BothconcentrationsofRNaseAreducedSMLRNAto
undetectable levels (Fig. 2). In addition, murine RNase inhibitor
(MRI)presentpriortoadditionofRNaseAcompletelyprecluded
degradationofSMLRNAbyRNaseA(Fig.2).Theseresultsdem-
onstrated that the ampliﬁcation product was derived from RNA,
andaslittleas1ngRNaseAcouldreduceSMLRNApresentinthe
phagepreparationtoundetectablelevels.Furthermore,upto5ng
RNase A was inactivated by MRI. These conditions sufﬁciently
inactivated RNase A and ensured that newly synthesized SML
RNA was not degraded during a test to detect viable bacteria.
DetectionofSMLgenerationduringphSP6-ProPolinfection
ofH37Rv.TodetermineifphSP6-ProPolsynthesizedSMLduring
infection of M. tuberculosis, we infected H37Rv bacteria (de-
scribed in Materials and Methods) with RNase A-treated phSP6-
ProPol. At 30 min postinfection, MRI was added. RNA was puri-
ﬁed from infected cells immediately (time 0.5), and at 3 and 4 h
postinfection. SML was ampliﬁed by RT-PCR. SML generation
was below detectable levels at 0.5 h, indicating that residual SML
RNA contained in the phSP6-ProPol stock was degraded by the
addition of RNase A. At 3 h, new SML generation occurred, and
the SML had increased by 4 h (Fig. 3).
Speciﬁcity of SML synthesis. To ensure that the 150-bp RT-
PCR product was not derived from mispriming of cellular RNA
during reverse transcription, we mock infected M. tuberculosis
H37Rv cells or infected them with RNase A-treated phSP6-
ProPol.Mock-infectedcellsdidnotreceiveRNaseAtoensurethat
all RNA in the sample, either intracellular or extracellular, was a
candidateformispriming.At4hpostinfection,RNAwaspuriﬁed
and ampliﬁed by RT-PCR using the primers DnSt and UpSt. The
150-bp SML ampliﬁcation product was observed only in cells in-
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ing. An RT-PCR product was observed in mock-infected (no
phage infection) M. tuberculosis, but it was signiﬁcantly larger
than the SML target and was clearly a result of nonspeciﬁc ampli-
ﬁcationofanM.tuberculosisRNA.Thisslower-migratingproduct
was also observed in phage-infected cells but at signiﬁcantly re-
duced levels compared to those in mock-infected cells. We hy-
pothesize that this may be due to RNase A-mediated destruction of
extracellular RNA from lysed cells present in the culture and/or de-
struction of intracellular host RNA by phage-encoded functions.
FIG1 DesignandcharacterizationofphSP6-ProPol.(A)TheSGMwascomprisedof2sectionscontainedwithinaXbaI-NotIrestrictionfragment:theSP6RNA
polymerasegene(SP6RNAPol)undertranscriptionalcontrolofthemycobacteriophageL5Pleftpromoter(openstar)andtheconsensusSP6promoterfusedto
theSML-encodingsequence(ﬁlledstar).TheSP6-SMLsectionisﬂankedby2transcriptionterminators:theupstreamterminator(ﬁlledcircle)isE.colirrnBT2
and precludes basal transcription through the SML-encoding sequence by host RNA polymerase; the downstream terminator (open circle) is the SP6 RNA
polymerase terminator from the region downstream of the SP6 phage major capsid subunit described by Dobbins et al. (22). After expression of SP6 RNA
polymerase from Pleft, the SML-encoding sequence downstream of the SP6 promoter was transcribed by SP6 RNA polymerase. SP6-dependent transcription of
theSML-encodingsequenceconstitutedgenerationoftheSML.SMLRNAcouldthenbeampliﬁedanddetectedusingprimersthatbindtheSML.(B)TheTM4
genomeisdepictedbythesolidblacklineatthetopoftheﬁgure.Expressionofphagegenesoccursononestrandofthegenome,andthedirectionoftranscription
is indicated by the dashed arrow above the phage genome. Transgenic functions inserted into TM4 are contained on a NotI fragment, which is indicated and
expanded.phAE142encodesanampicillinresistancecassette(Ampr)andanoriginofreplication(oriE)formaintenanceandselectionofthephasmidinE.coli.
phAE142alsoencodestheluciferaseopenreadingframefusedtoPleft.phSP6-ProPolwasderivedfromphAE142andreplacedtheluciferase-encodingXbaI-NotI
fragment with the XbaI-NotI SGM. In addition, phSP6-ProPol contained a kanamycin resistance cassette (Kmr) in place of phAE142 Ampr.P left transcription
occurred on the strand opposite the endogenous phage functions in both phAE142 and phSP6-ProPol. The binding sites and orientation of oligonucleotide
primersUl53-UpSt-113348andUl53-DnSt-112112(UpStandDnSt,respectively)usedfordetectionofSMLgenerationandthoseusedtocharacterizetransgene
structure in phSP6-ProPol are indicated. (C) Phage eluted from primary (1°) plaques originating with transformation of 2 independent phSP6-ProPol-Kan
phasmid DNA clones (#4 and #5), as well as phAE142 phasmid DNA, into mc2 4502 were added to a PCR with the primers PLLF and TM4-50133.52. Phasmid
DNA with and without the addition of MP buffer was included as controls. PLLF and TM4-50133.52 were predicted to generate a 667-bp product using
phSP6-ProPol as a template, compared to a 181-bp product when phAE142 was the substrate. Products were separated on a 2% agarose gel and visualized by
ethidium bromide staining. Locations of DNA size markers are indicated. (D) Phage eluted from the 1° plaques in panel C were ampliﬁed using primers PLLU
and PLLD, which were predicted to mediate ampliﬁcation of 2,854-bp and 1,882-bp products in phSP6-ProPol and phAE142, respectively. Products were then
separated on a 1% agarose gel and visualized by ethidium bromide staining. The locations of DNA size markers are indicated.
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SP6 promoter. Although Fig. 4 demonstrates that SML RNA was
synthesized during infection of M. tuberculosis, it was not clear if
transcription was initiated by SP6 RNA polymerase at the SP6
promoter or by the host cell RNA polymerase from an upstream,
cryptic phage promoter. It was important to verify that SML was
transcribed by SP6 polymerase, because bacteriostatic antibiotics
that inhibit host protein synthesis machinery (translation) leave
the cellular transcriptional machinery relatively unaffected (13).
With phage infection, this healthy machinery would immediately
transcribetheSMLifacryptichostpromoterwasupstreamofthe
consensus SP6 promoter. This could result in false-positive re-
ports of resistance to a translational inhibitor drug. To determine
if transcripts initiated from an upstream cryptic phage promoter
synthesized SML, we puriﬁed RNA from phSP6-ProPol-infected
H37Rvcellsharvestedat4handampliﬁeditbyRT-PCRusingone
of 2 primer pairs. The ﬁrst pair, consisting of DnSt and UpSt,
mediated ampliﬁcation of the 150-bp SML sequence. The second
pair, comprised of DnSt and SP6-Dep-UpSt, mediated ampliﬁca-
tionofa215-bpproduct.SP6-Dep-UpStoverlappedtheSP6pro-
moter but not the transcription initiation site, so could not am-
plify an RT-PCR product if SML RNA transcription was initiated
at the SP6 promoter. However, if a cryptic phage promoter medi-
atedSMLsynthesis,a215-bpRT-PCRproductwouldbeobserved
using this primer pair (Fig. 5A). In Fig. 5B, an RT-PCR product
was obtained using the primers DnSt and UpSt. However, al-
though the primers DnSt and SP6-Dep-UpSt mediated PCR am-
pliﬁcationofthe215-bpproductwhenthesubstratewasaplasmid
containing the SGM, we observed no product when the substrate
wasRNAderivedfromphSP6-ProPol-infectedH37Rvcells.These
results showed that SML synthesis was initiated at the SP6 pro-
moter and was dependent upon accumulation of SP6 RNA poly-
merase.
SML phage reported H37Rv susceptibility to ﬁrst-line
anti-TB antibiotics. To determine if phSP6-ProPol could accu-
rately report susceptibility to ﬁrst-line anti-TB drugs, we left M.
tuberculosisH37Rvuntreatedortreatedthebacteriaforeither16h
or 40 h with rifampin (RIF), isoniazid (INH), streptomycin
FIG 2 SML RNA present in phSP6-ProPol stocks. A crude phSP6-ProPol
preparation (108 PFU) was either left untreated or treated with MRI to a ﬁnal
concentration of 1 U/l. Either 5 ng ()o r1n g( ) RNase A was then
added,andthemixturewasincubatedfor30minat37°C.Afterpuriﬁcationof
RNA and digestion with DNase I, reverse transcription was carried out using
the DnSt primer. After reverse transcription but prior to PCR, cDNA from
eachsamplewasdiluted1:10toestimatea10-foldsignalreduction.Theprim-
ers DnSt and UpSt were then used to amplify a 150-bp section of SML cDNA
using PCR. Products were separated on a 2% agarose gel and visualized by
ethidium bromide staining. The locations of DNA size markers are indicated.
FIG 3 SML detection occurs at 4 h postinfection (p.i.). H37Rv was infected
withphSP6-ProPol.RNaseAwasaddedtophSP6-ProPolpriortoinitiationof
infection, and MRI was added at 0.5 h p.i. At 0.5, 3, and 4 h p.i., RNA was
puriﬁed, digested with DNase I, and ampliﬁed using RT-PCR. Products were
then separated on a 2% agarose gel and visualized by ethidium bromide stain-
ing. The locations of DNA size markers are indicated.
FIG4 SML generation observed in phSP6-ProPol-infected cells. H37Rv cells
wereeithermockinfectedorinfectedwithphSP6-ProPol.RNAwaspuriﬁedat
4 h p.i., and SML generation was detected using RT-PCR. Products were then
separated on a 2% agarose gel and visualized by ethidium bromide staining.
The locations of DNA size markers are indicated.
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fected with phSP6-ProPol for 4 h. RNA was puriﬁed, followed by
ampliﬁcation of the SML using RT-PCR. Dilutions (101 and
102)oftheuntreatedcontrolcDNAwereampliﬁedtoprovidean
estimationofSMLreductionbetweenuntreatedanddrug-treated
H37Rv.Atboth16and40hofdrugexposure,weobservedaclear
difference in SML generation between the untreated and drug-
treated samples (Fig. 6). Bacteria treated with rifampin and strep-
tomycin generated no detectable SML after either 16 or 40 h of
treatment;inbacteriatreatedwithisoniazidandethambutol,both
cell wall-active drugs, SML synthesis was present in a small quan-
tity after 16 h of drug treatment, but SML production was com-
pletely abolished by 40 h of drug treatment. The level of SML
generation in the 16-h samples was approximately 10-fold lower
than that for untreated controls, since the ampliﬁcation product
derived from isoniazid- and ethambutol-treated cells was less in-
tense than that with a 101 dilution of cDNA from the untreated
control. These data showed that the SGM encoded in phSP6-
ProPolcouldreportM.tuberculosisdrugsusceptibilityinlessthan
1 day for metabolically active drugs and less than 2 days for drugs
that affect cell wall synthesis.
phSP6-ProPoldetectsM.tuberculosisresistancetorifampin
and ethambutol. To determine if phSP6-ProPol could report
drug-resistant M. tuberculosis, two mono-resistant strains, one
RIFrandtheotherEMBr,wereuntreatedortreatedwithrifampin
andethambutolfor16handtheninfectedwithphSP6-ProPol.At
4hpostinfection,RNAwaspuriﬁedandSMLwasampliﬁedusing
RT-PCR. A dilution (101) of the cDNA derived from both the
untreated and ethambutol-treated RIFr strain was ampliﬁed to
provide an estimation of SML reduction by ethambutol (Fig. 7).
Treatment of the RIFr strain with ethambutol (to which it is sus-
ceptible) resulted in an approximately 10-fold reduction in SML
generationcomparedtoresultsfortheuntreatedcontrol,whereas
there was no observable reduction in SML generation after treat-
ment with rifampin. Treatment of the EMBr strain with rifampin
(to which it is susceptible) resulted in no detectable SML genera-
tion, reﬂecting the potent activity of rifampin in this assay; SML
generation was not decreased after ethambutol treatment. These
datademonstratedthatrifampinandethambutolresistancecould
beaccuratelydetectedbytheSGMencodedinphSP6-ProPolafter
as little as 16 h of drug treatment.
DISCUSSION
Fordrugswhoseresistancegenesareknown,nucleicacidtestscan
simultaneously provide microbial identiﬁcation and resistance
detectionthatcanfacilitateselectionofeffectivedrugsforindivid-
ual patients. But the resistance mechanisms of most drugs either
are very complex, affected by drug efﬂux rather than genetic
changes, or are totally unknown. We designed and constructed a
novelphage-basedreportersystem(theSGM)thatcouldproduce
anengineerednucleicacidmarkerofcellviabilityandsusceptibil-
ity to any active drug, the SML. When the SGM was incorporated
into a mycobacteriophage, phage-infected M. tuberculosis pro-
duced SML in sufﬁcient quantity to be easily ampliﬁed and de-
tected. Moreover, when we treated M. tuberculosis with drugs to
whichthebacteriaweresusceptible,SMLproductionwasmeasur-
ably diminished or undetectable.
Because rifampin and streptomycin interfere directly and im-
mediately with phage gene expression, the reduction in SML pro-
duction by susceptible M. tuberculosis can be detected as early as
16 h after introduction of the drug. Isoniazid and ethambutol do
not have the same drug effect time course as rifampin or strepto-
mycin, since they act on the cell wall. With a replication time of
24h,exposureofM.tuberculosistocell-wall-activedrugsrequires
sufﬁcient time to affect the integrity of the wall, so a longer drug
exposureisrequiredtoobserveacompleteabsenceofSML.How-
ever, SML production was still substantially (10-fold) reduced
with these drugs at 16 h. We expect that antibiotics used to treat
multidrug-resistantTB(MDR-TB)andextensivelydrug-resistant
TB (XDR-TB), speciﬁcally ﬂuoroquinolones and the injectable
aminoglycosides,willexhibitSMLproductioninamannersimilar
to that with rifampin and streptomycin, because they interfere
directly with the host cell machinery required for phage gene ex-
FIG 5 Detection of transcription by a cryptic promoter upstream of the SP6
promoter. (A) SP6 promoter-SML transcription unit and the locations of
primers UpSt and DnSt, used to amplify SML RNA, are indicated. The primer
SP6-Dep-UpStoverlapstheSP6promoterandterminatesonenucleotide5=to
thetranscriptioninitiationsiteforSP6polymerase.(B)RNApuriﬁedat4hp.i.
from H37Rv M. tuberculosis infected with phSP6-ProPol was digested with
DNase I prior to reverse transcription with the DnSt primer. A portion of
cDNAwasthenleftundilutedordiluted1:10andwasPCRampliﬁedusingthe
primers DnSt and UpSt or DnSt and SP6-Dep-UpSt. The targeting plasmid
pSP6-ProPol-Kanwasincludedinseparateampliﬁcationreactionsasacontrol
for successful PCR using each primer set. Products were then separated on a
2% agarose gel and visualized by ethidium bromide staining. The locations of
DNA size markers are indicated.
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taneously diagnose MDR- and XDR-TB by interrogating M. tu-
berculosis in sputum for resistance to rifampin (a surrogate for
MDR-TB)andbothkanamycinandciproﬂoxacin(asurrogatefor
XDR-TB).
The SGM is a new genetic approach to detect microbial drug
susceptibility and resistance: it combines the sensitivity and accu-
racy of phenotypic antibiotic susceptibility testing (measures the
activity of any drug) with the power of nucleic acid tests to detect
veryfewmicroorganismsinamatterofhours.Onestudydemon-
strated that after treatment of M. tuberculosis cultures with isoni-
azidorrifampin,antigen85BmRNA,whichhasaveryshorthalf-
life, decreases rapidly and accurately reports drug susceptibility
and resistance (14). To our knowledge the effectiveness of this
approachhasnotbeenvalidateddirectlywithclinicalsamples.Itis
possible that the complex mixture of M. tuberculosis nucleic acid
from lysed, dying, and viable cells present in sputum may con-
found this approach. SGM phage may prove to be more suitable
for interrogation of the drug susceptibility proﬁle of M. tubercu-
losis present in clinical samples because the SML is an artiﬁcial
sequence not present in sputum.
Theprototypeassaydescribedinthisreportdemonstratesthat
theSGMfunctionedasdesignedandaccuratelyreportedthedrug
susceptibility proﬁle of M. tuberculosis. However, this is still a
complex assay, and the limits of detection in clinical samples are
unknown. For it to be universally useful as an antibiotic suscepti-
bilitytestinaclinic,werealizethatwemustcontinuetoreﬁnethe
process and design a robust assay. Our goal is to evolve a rapid
molecular diagnostic test to identify viable M. tuberculosis and
rapidly and accurately report M. tuberculosis susceptibility to any
drug to ensure a proper choice of effective drugs for patients. The
prototype described above provides us with a road map and a set
of tools to make that happen.
MATERIALS AND METHODS
Bacterial strains, phage, and propagation. M. smegmatis mc2 4502 and
phage phAE142 were obtained from William Jacobs at Albert Einstein
College of Medicine (Table 1). phAE142 and phSP6-ProPol were propa-
gated using mc2 4502 as described previously (5). H37Rv was maintained
in 7H9 broth supplemented with Middlebrook oleic acid-albumin-
dextrose-catalase (OADC) and 0.01% Tween 80. Electrocompetent Esch-
erichia coli DH10B and chemically competent E. coli DH5 cells were
obtained from Invitrogen Corporation. Both the rifampin-resistant
(RIFr) and ethambutol-resistant (EMBr) M. tuberculosis strains used in
this study were created and isolated from H37Rv by Sequella, Inc., and
weremaintainedbythesameprotocolsusedforH37Rv.TheMICofRIFr
M. tuberculosis to rifampin and EMBr M. tuberculosis to ethambutol was
32 g/ml (each). Both resistant strains were susceptible to all other
antituberculosis drugs tested (V. Reddy, personal communication).
Molecular biology reagents. BssHII, NotI, XbaI, Antarctic phospha-
tase, MRI, avian myeloblastosis virus reverse transcriptase, DNase I, and
T4DNAligasewereobtainedfromNewEnglandBiolabs.Taqpolymerase
and deoxyribonucleotides were obtained from GenScript Corporation.
FIG6 phSP6-ProPol determined H37Rv susceptibility to ﬁrst-line antitubercular antibiotics with a high signal-to-noise ratio. H37Rv was either left untreated
or treated with rifampin, isoniazid, streptomycin, or ethambutol for 16 h or 40 h. Bacteria were then infected with phSP6-ProPol for 4 h. RNA was isolated,
puriﬁed,andampliﬁedusingRT-PCR.Theresultantproductwasseparatedby2%agarosegelelectrophoresisandwasstainedwithethidiumbromide.Dilutions
(1:10 and 1:100) of cDNA from the untreated controls were made prior to PCR ampliﬁcation to provide a semiquantitative estimation of the effect of eachdrug
on SML synthesis during infection of drug-susceptible M. tuberculosis. The locations and molecular weights of DNA size markers in lane M and the location of
the SML signal are indicated.
FIG 7 phSP6-ProPol can detect M. tuberculosis drug resistance. RIFr M.
tuberculosisandEMBrM.tuberculosiswereeitherleftuntreatedortreatedwith
rifampin or ethambutol for 16 h. Bacteria were then infected with phSP6-
ProPol for 4 h. RNA from each sample was then puriﬁed and ampliﬁed using
RT-PCR. The resultant product was separated by 2% agarose gel electropho-
resis and visualized by staining with ethidium bromide. A 1:10 dilution of
cDNA derived from the untreated and ethambutol-treated phSP6-ProPol-
infected RIFr strain was made prior to PCR ampliﬁcation to provide a semi-
quantitative determination of the reduction of SML synthesis by ethambutol
in this strain. The locations of DNA size markers are indicated.
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Operon. The RNeasy kit with RNase-free water was obtained from Qia-
gen.Ampicillin,kanamycin,rifampin,isoniazid,streptomycin,ethambu-
tol, and RNase A were obtained from Sigma-Aldrich.
Generation of phSP6-ProPol. Mycobacteriophage TM4 is a well-
characterized and versatile model for the construction and characteriza-
tion of reporter mycobacteriophages (15–17). phAE142 is TM4 into
whichatransgeniccassettehasbeeninsertedandencodesﬁreﬂyluciferase
under the transcriptional control of the mycobacteriophage L5 Pleft pro-
moter(5),aswellastwoelementsderivedfromthecosmidcloningvector
SuperCos-1(5,18–20)necessaryformaintenanceofthephagegenomein
E. coli as a phasmid: an origin of replication and an ampicillin resistance
cassette. To create the phasmid phMM-001, phAE412 genomic DNA was
prepared as described previously (21), circularized by intramolecular li-
gation with T4 DNA ligase, and transformed into electrocompetent
DH10B according to the manufacturer’s directions. Transformants were
selectedonLuriabrothagarsupplementedwith100g/mlampicillin.To
create the targeting vector pYUB-Bss, which contains the transgenic frag-
ments present in phAE142, phMM-001 DNA was isolated and digested
withBssHII,whichdoesnotcutinthetransgenicfragment.Thisdigestion
mixturewasthendiluted,andcircularDNAmoleculesweregeneratedby
addition of T4 DNA ligase. The transgenic fragment was recovered by
transformation into competent DH5 according to the manufacturer’s
directions, followed by selection on Luria broth agar supplemented with
ampicillin.
SGM synthesized de novo by GenScript Corporation was maintained
in the plasmid pUC57 and designated pUC57-SP6-ProPol. To create
phSP6-ProPol, we digested pUC57-SP6-ProPol with NotI and XbaI, fol-
lowed by gel puriﬁcation of the SGM. The SGM was then ligated into
NotI-andXbaI-digestedpYUB-BsstocreatepSp6-ProPol.Theampicillin
resistance gene in pSp6-ProPol was then replaced with the kanamycin
resistancegenebylambdaredrecombineering(4)tocreatepSp6-ProPol-
Kan.pSp6-ProPol-KanwasthendigestedwithNotI,dephosphorylatedby
incubation with Antarctic phosphatase, gel puriﬁed, ligated with NotI-
digested phMM-001, and electroporated into DH10B. Kanamycin-
resistantcolonieswereexpandedandassayedbyPCRforcorrectinsertion
of the SGM into phMM-001 using the primers pLeft-LocusForward and
TM450133-52. Phasmid DNA was then isolated and electroporated into
electrocompetent mc2 4502 to create infectious phSP6-ProPol, as de-
scribed elsewhere (21). Individual plaques were harvested and crude
stocks of phSP6-ProPol were obtained by elution from conﬂuently lysed
agarNobleoverlaysusingMPbuffer(50mMTris,150mMNaCl,10mM
MgCl2, 2 mM CaCl2 [pH  7.6]). Phage were maintained at 2 
109 PFU/ml in MP buffer at 4°C.
Preparation of M. tuberculosis prior to phage infection. Prior to
phage infection, cultures of H37Rv were washed 3 times with 7H9 broth
supplemented with OADC, diluted to an optical density at 600 nm
(OD600) of 0.1 to 0.2, and incubated overnight at 37°C with shaking. For
susceptibilitytesting,antibioticswereaddedimmediatelyafterwashingto
a ﬁnal concentration of 2 g/ml rifampin, 0.2 g/ml isoniazid, 2 g/ml
streptomycin, and 7.5 g/ml ethambutol.
phSP6-ProPol infection. At phage infection, we added 5 ng of RNase
At o1 0 0l phSP6-ProPol, and 10 l of phSP6-ProPol containing RNase
A was added to 100 l washed H37Rv, RIFr M. tuberculosis,o rE M B r M.
tuberculosisandincubatedat37°C.MRIwassubsequentlyaddedbetween
0.5 h and 2 h postinfection.
RNA puriﬁcation. RNA released into the culture supernatant after
lysisofphage-infectedcellsbyphage-encodedlyticfunctionswaspuriﬁed
using the RNeasy kit according to the manufacturer’s directions. Brieﬂy,
buffer RLT was added to samples, followed by the addition of 100% eth-
anol, and RNA was puriﬁed using RNeasy spin columns. RNA was eluted
in 50 l RNase-free water, and MRI was added to a ﬁnal concentration of
1U / l. After the addition of buffer RLT but before that of ethanol, sam-
ples containing M. tuberculosis strains were sterile ﬁltered using 0.22-m
Acrodisc syringe ﬁlters (Pall Corporation).
RT-PCR. Sixteen microliters of puriﬁed RNA was treated with 4 U
DNase I for 30 min at 37°C in a total reaction volume of 20 l. The
solutionwasthenadjustedto5mMEDTAandheatedat75°Cfor10min.
TABLE 1 Mycobacteriophages, bacterial strains, plasmids, and oligonucleotides used in this study
Mycobacteriophage,
plasmid, strain,
or oligonucleotide Description or sequence Reference
Mycobacteriophage
phAE142 Mycobacteriophage TM4-based luciferase reporter phage 5
phSP6-ProPol Prototype SGM phage This study
Plasmids
phMM-001 Ampr phasmid derived from phAE142; maintained in E. coli This study
pYUB-Bss Ampr low-copy-number targeting vector encoding E. coli origin of replication
and Pleft promoter-driven luciferase gene; derived from BssHII fragment
of phMM-001
This study
pUC57-SP6-ProPol Ampr high-copy-number E. coli plasmid containing SGM This study
pSP6-ProPol SGM from pUC57-SP6-ProPol inserted into pYUB-Bss in place of Pleft promoter
and luciferase gene
This study
pSP6-ProPol-Kan pSP6-ProPol with Ampr gene replaced with Kanr gene This study
Bacterial strains
DH5 E. coli cloning strain 23
DH10B E. coli cloning strain 24
mc2 4502 M. smegmatis strain constitutively expressing mycobacteriophage L5 gp71
polypeptide to downregulate Pleft promoter activity during growth of
reporter phage stocks
5
RIFr M. tuberculosis strain Rifampin-resistant H37Rv derivative generated at Sequella, Inc. Unpublished
EMBr M. tuberculosis strain Ethambutol-resistant H37Rv derivative generated at Sequella, Inc. Unpublished
Oligonucleotides
UL53-DnSt-113348 5= GACCCATGGGCGGGGTCGTT 3= This study
UL53-UpSt-112112 5= AGTGCTTTGCCGCCAAATGC 3= This study
PLLF 5= GTGGCTGTCAAGCCCTAATC 3= This study
TM450133-52 5= GTGTCGTGCTCGGTAACCTC 3= This study
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using10Ureversetranscriptasefor30minat55°CwiththeprimerUL53-
DnSt-113348ataﬁnalconcentrationof1Minatotalreactionvolumeof
20 l. Two microliters of cDNA, or a dilution of the cDNA in water, was
then added to a 25-l hot-start PCR mixture using the primers UL53-
DnSt-113348 and UL53-UpSt-112112 at ﬁnal concentrations of 120 M
and40M,respectively.Ampliﬁcationwasperformedfor35cyclesusing
an annealing temperature of 55°C. Ten microliters of the ampliﬁcation
product was then separated by electrophoresis through a 2% agarose gel
impregnated with 500 ng/ml ethidium bromide. An internal ampliﬁca-
tioncontrolwasnotperformedbecauseeachdrugdifferentiallyaffectsthe
levelofintracellularRNAinsusceptiblemycobacteria.Furthermore,each
hasvariableeffectsoncellgrowth,leadingtodifferencesinbacterialnum-
bers between the drug-treated samples. Normalizing the amount of RNA
between all samples would therefore underreport the dynamic range of
the assay.
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